TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04728191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: physiotherapeutical instructions and training as described.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: physiotherapeutical instructions and training as described.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care as described.
Study: NCT05690750

Intervention type: OTHER
Intervention: No intervention
Description: No intervention as this is an observational study.
Study: NCT04728191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care as described.
Study: NCT05276895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin and Fisetin tab.
Description: 1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
Study: NCT05025813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Delivery of neo-adjuvant Pembrolizumab
Study: NCT05139615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD418
Description: Participants will receive a single dose of APD418 as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD418
Description: Participants will receive a single dose of APD418 as an IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of APD418 matching placebo as an IV infusion.
Study: NCT05386537

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MyoMo orthosis and VR games
Description: Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyoPro robot only
Description: Using the MyoPro wearable robotic orthosis only

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoPro robot only
Description: Using the MyoPro wearable robotic orthosis only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Games only
Description: Using VR-video games only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Games only
Description: Using VR-video games only

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: conventional UE therapy at a rehabilitation facility
Study: NCT05276895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules
Description: quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for one week every 3 weeks over 15 weeks
Study: NCT05673109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC176
Description: AC176 will be given orally (PO) on a 28-day cycle.
Study: NCT05003687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: solution, orally (Parts A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: solution, orally (Parts A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution, orally (Part A only)
Study: NCT06119828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding education for family members
Description: The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: receiving routine breastfeeding training
Description: After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
Study: NCT05730049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
Study: NCT06210165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine and atropine
Description: IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
Study: NCT05759013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath synchronized abdominal NMES
Description: Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham breath synchronized abdominal NMES
Description: Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
Study: NCT05858346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Behavior Therapy
Description: TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Social Anxiety Disorder
Description: To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
Study: NCT05711225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.
Description: Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
Study: NCT05184114

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Magnetic Resonance, Blood Tests
Description: Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Blood Tests
Description: Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Blood Tests
Description: Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance, Blood Tests
Description: Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
Study: NCT06397703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide, Degarelix or Relugolix
Description: Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy/radiosurgery (SBRT)
Description: SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Inter-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiation therapy/radiosurgery (SBRT)
Description: SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Inter-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.
Study: NCT04846790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature Only
Description: See above for description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature+Mindfulness
Description: See above for description.
Study: NCT05291429

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OVR Health's VR experience
Description: Virtual reality experience

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OVR Health's VR experience
Description: Virtual reality experience
Study: NCT05661500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Darama Group
Description: Postmortem care training given by creative drama method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Education Group
Description: Postmortem care training given by classical education method
Study: NCT05543109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 mic/kg during induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 mic/kg during induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 3mg/kg during induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 3mg/kg during induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.9 mg/kg during induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.9 mg/kg during induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 2-3% during maintanance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 2-3% during maintanance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
Study: NCT05543005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maternal voice intervention
Description: maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
Study: NCT06167421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique
Description: The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique
Description: Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
Study: NCT05498051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node identification
Description: Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
Study: NCT05519306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Practice
Description: Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
Study: NCT06456359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Signifor
Description: Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
Study: NCT06270732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMentalize Program (iMentalize)
Description: This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)
Description: This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)
Description: This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment.
Study: NCT06001515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual scan protocol
Description: one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: triple scan protocol
Description: 3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
Study: NCT00362219

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel with no active ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine - .25 mg
Description: gel with 0.25 mg morphine per 100cm2 square of wound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Gel with 0.75 mg morphine per 100cm2 square of wound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Gel with 1.25 mg morphine per 100cm2 square of wound.
Study: NCT05545800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin+empagliflozin+insulin glargine
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. The dose of metformin will be initiated at 0.5 grams three times a day (the maximum dose is 2g/day); the dose of empagliflozin will be 10 milligrams once a day; insulin glargine will be received once daily at bedtime and the dose will be initiated at the 50% of 0.4-0.5 units/kg/day. All groups received counseling on lifestyle modification.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: premixed insulin analogues
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
Study: NCT05991804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation added to inpatient rehabilitation
Description: Non-invasive electrical stimulation delivered over the spine, targetting movement of the upper limbs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient rehabilitation alone
Description: Standard inpatient rehabilitation given at the Royal National Orthopaedic Hospital NHS Trust